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SUMMARY
Introduction Ehrlichiosis is a bacterial zoonosis transmitted by hematophagous arthropods – ticks. In 
humans, it occurs as monocytic, granulocytic, and ewingii ehrlichiosis. Pathological process is based on 
parasitic presence of Ehrlichia organisms within peripheral blood cells – monocytes and granulocytes.
Case Outline Fifty-two year old patient was admitted to hospital due to high fever of over 40°C that 
lasted two days, accompanied with chills, muscle aches, malaise, loss of appetite, headache, confusion, 
breathing difficulties, and mild dry cough. The history suggested tick bite that occurred seven days before 
the onset of disease. Doxycycline was introduced and administered for 14 days, causing the disease to 
subside. Indirect immunofluorescence assay was used to analyze three serum samples obtained from this 
patient for Ehrlichia chaffeensis antibodies, and peripheral blood smear was evaluated for the presence 
of Ehrlichia and Ehrlichia aggregation into morulae.
Conclusion Ehrlichiosis should be considered in each case where there is a history of tick bite together 
with the clinical picture (high fever, chills, muscle aches, headache, generalized weakness and malaise, 
and possible maculopapular rash). The presence of Ehrlichia chaffeensis antibodies was confirmed in a 
patient with the history of tick bite, appropriate clinical picture and indirect immunofluorescence as-
say. This confirmed the presence of human monocytotropic ehrlichiosis, a disease that is uncommonly 
identified in our country.
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INTRODUCTION
Ehrlichiosis, as human infectious disease, was 
described in 1986, although Ehrlichia has been 
studied as a cause of disease in animals until 
1968, when Ehrlichia canis was identified as 
the cause of disease of a large number of mili-
tary dogs in Vietnam. The similarity between 
E. canis and E. sennetsu (previously known as 
Rickettsia sennetsu), causing fever in humans 
in Japan, was then observed. Recent findings 
have suggested that Ehrlichiae, together with 
Rickettsiae, form a subgroup of Proteobacte-
ria [1]. Bacteria from the Ehrlichia genus were 
classified to the Anaplasmataceae family [2]. 
Based on their genetic characteristics, Ehrlichia 
organisms were divided into 3 genogroups. Ge-
nogroup I includes E. chaffeensis (cause of hu-
man monocytotropic ehrlichiosis – HME), E. 
canis, and E. ewingii. Genogroup II (Anaplasma 
group) includes Anaplasma phagocytophilum – 
human granulocytic ehrlichiosis – HGE, and 
E. equi. Genogroup III (called Neorickettsiae) 
includes E. sennetsu and E. risticii [1].
The first case of human ehrlichiosis, similar 
to E. canis, was described in the USA in late 
1980s [3]. Patients with specific antibodies to 
E. chaffeensis were later described in other con-
tinents and countries: Israel [4], Thailand [5], 
and Argentina [6]. E. chaffeensis was isolated 
from the tick Ixodes ricinus in Germany [7] 
and Bulgaria [8]. The human infections caused 
by E. chaffeensis were confirmed by numerous 
seroepidemiological studies in Italy [9], Czech 
Republic [10], Portugal [11], Slovenia [12], and 
Croatia [13], while there has been one case re-
ported in Serbia [14]. Retrospective studies 
showed that Ehrlichiae, as causes of infectious 
diseases, had been present in human popula-
tion even before 1980s [15].
The aim of this paper was to present clinical 
characteristics of the serologically confirmed 
case of ehrlichiosis in a patient who had previ-
ously been bitten by a tick.
CASE REPORT
Fifty-two year old patient was admitted to De-
partment for Infectious Diseases of General 
Hospital in Subotica due to high fever of over 
40°C that lasted for two days and was accom-
panied by chills, muscle aches, malaise, loss of 
appetite, headache, confusion, breathing diffi-
culties, and mild dry cough. Seven days before 
the onset of disease, the patient noticed a tick 
in his scrotal region and removed it himself. Be-
fore admission to hospital, the patient took anti-
pyretics only. On admission, he had high fever, 
was adynamic to prostration, and confused. The 
remaining physical findings appeared normal, 
as well as local findings at the site of tick bite.  
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Laboratory findings immediately upon admission were 
the following: WBC 2.9×109/L, platelets 72×109/L, RBC 
4.44×1012/L, hemoglobin 129 g/L, AST 82 U/L (normal 
level: up to 37), ALT 55 U/L (normal level: up to 42), CK 
1890 U/L (normal level: up to 195), and CRP 29.2 mg/L. 
Urine examination showed normal results. Blood and urine 
cultures were negative to Mycobacterium tuberculosis. Se-
rologic reactions to Rickettsia prowazekii, Coxiella burnetii, 
Brucella abortus, Borrelia burgdorferi, as well as TPHA were 
negative. Furthermore, serologic reactions to EBV, CMV 
and HSV were negative. RF and ANA were also negative. 
Lung X-ray, and the abdominal and urinary tract ultra-
sound suggested normal findings. Peripheral blood smear 
showed morulae in small number of monocytes (less than 
10%) staining darker than the rest of the monocytes.
On the second day of hospital stay, doxycycline was 
introduced at a dose of 2×100 mg orally, and on the follow-
ing day, the patient’s fever subsided. Treatment lasted 14 
days, after which the patient had no subjective complaints 
and the physical findings were normal.
Laboratory findings at discharge: WBC 7.5×109/L, plate-
lets 220×109/L, RBC 4.1×1012/L, hemoglobin 120 g/L, AST 
32 U/L, ALT 34 U/L, CK 155 U/L, CRP 15.2 mg/L. During 
the following six months, the patient used to come for regu-
lar controls and he had no subjective complaints, while his 
physical and laboratory findings remained normal.
At the Department for Immunology of the Military 
Medical Academy, indirect immunofluorescence assay 
was used to analyze three serum samples from this patient 
for E. chaffeensis antibodies, and peripheral blood smear 
was evaluated for the presence of Ehrlichia and Ehrlichia 
aggregation into morulae. Serum samples were taken on 
days 7 (July 24, 2006), 14 (July 31) and 50 (September 5) 
of the illness, and the titers of IF antibodies were < 1:32, 
1:64, and 1:128, respectively. The peripheral blood smear 
was dated July 19, 2006. 
Indirect Immunofluorescence Assay (IFA)
The antigen for identification of E. chaffeensis antibodies 
(Lot no. 02-0266N) was obtained as a suspension of E. chaf-
feensis replicated in canine monocytes. The suspension was 
spread over 8-field microscopy slides, dried at room tem-
perature for at least three hours, and fixed with cold acetone 
(Merck pro analysi) for 10 minutes at -18°C. The slides were 
then dried 10 minutes at room temperature, and immedi-
ately used as an antigen, or stored for later use at -20°C.
The immune control serum was human serum obtained 
from convalescents infected with E. chaffeensis with titers 
of 128 or higher. The control negative serum was human 
serum negative to E. chaffeensis antibodies at a dilution 
of 1:16.
The IFA reaction
After brief rehydration, patient’s sera were applied to 
prepared antigen in series of PBS dilutions ranging from 
1:16 to 1:256. After 30 minutes of humidity chamber in-
cubation at 37°C and PBS wash-out, in order to remove 
antibodies not bound to antigen, a mixture of fluorescein 
labeled goat antihuman IgG (INEP, Belgrade) was added, 
as well as Evans blue for better contrast when reading the 
reaction. After 30 minutes of humidity chamber incu-
bation at 37°C, slides were washed out, dried, and after 
adding glycerin, the IFA reaction was studied using Leitz 
fluorescent microscope (at 400× magnification). The last 
serum dilution showing observable immunofluorescence 
in monocyte cytoplasm with good positive and negative 
control was considered to be the titer of E. chaffeensis an-
tibodies.
DISCUSSION
The disease of the humans known as humane monocytic 
or monocytotropic ehrlichiosis is caused by Ehrlichia chaf-
feensis. It dwells and replicates in the cytoplasm of certain 
host cell types, mainly neutrophil leukocytes, leukocytes 
and monocytes, within vacuoles that are bound to cellular 
membrane. The name of the disease HME suggests the 
tropism of the organism toward peripheral blood mono-
cytes [13]. Until now, only one report on HME in Serbia 
has been published. Dokić et al. [16] presented the case of 
HME in a patient admitted to Military Medical Academy. 
The HME is a complex zoonosis. The causing organ-
ism persists in the nature through the infection of vari-
ous mammals. Dogs, wolves and deer are considered to 
be the primary reservoirs of Ehrlichia chaffeensis. Fox and 
goats have been experimentally infected as well. The pri-
mary vector is a tick Amblyomma americanum. Ehrlichia 
chaffeensis may also be transmitted by a tick Dermacentor 
variabilis [17]. Most ehrlichiosis cases have history of tick 
bites (as in our patient), although in 32% of cases this in-
formation may be missing [18]. Therefore, the absence of 
definite tick attachment should never dissuade physician 
from considering the diagnosis of HME.
There is no specific clinical sign that would help in dis-
tinguishing this condition. In both HME and HGE, the 
symptoms may vary in their intensity, ranging from mild 
disease to life- threatening conditions. The most common 
symptoms are elevated body temperature (>90%), head-
ache (>85%), fever, muscle aches (>80%), nausea (40%), 
vomiting (40%), loss of appetite (40%), overall weakness 
and malaise (>80%), and confusion (20%). The diffuse 
skin changes are uncommon (10%), and if present, they 
are manifested as maculopapular rash without any predi-
lection. The central nervous system infection is present 
in 20% of patients with HME and may manifest as aseptic 
meningitis with lymphocytic pleocytosis and elevated pro-
tein level in cerebrospinal fluid, cranial nerve neuropathy 
or encephalopathy [19, 20]. Because the signs and symp-
toms are nonspecific, the clinicians must frequently incor-
porate clues from the clinical and epidemiologic history 
and consider other features. Most of these symptoms and 
signs were present in our patient, and the history of tick 
bite made our diagnosis of HME easier.     
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The etiological diagnosis of human ehrlichiosis is based 
on serological diagnostics or identification of causative mi-
croorganism in the elements of peripheral blood. In the 
peripheral blood smear, morulae are found in granulocytes 
(25-80%) and in monocytes (less than 10%). Morulae are 
cytoplasmic vacuoles in which Ehrlichia replicates. The 
most commonly used staining method is Wright’s stain. 
The serological reaction that is used for diagnosis is indi-
rect immunofluorescence (IF) assay [21]. According to the 
Center of Disease Control (CDC), the first sample should 
be taken as early as possible, preferably in the first week 
of symptoms, and the second sample should be taken 2 
to 4 weeks later [22]. The IF assay is considered positive 
if there is an increase or decrease in titer of antibodies 4 
times or more during the disease, with minimum titer of 
1:80. In our patient, the IF assay was in accordance with 
these data, and the expected higher levels of antibody titer 
were not obtained, most probably due to early antibiotic 
treatment (5th day of the disease).
Doxycycline is a treatment of choice for any type of 
human ehrlichiosis. It is very efficient; it stops disease pro-
gression and leads to recovery [23]. An optimal duration 
of therapy has not been established; current recommenda-
tions for HME treatment are at least 3 days after the fever 
subsides and until the clinical improvement is evident, 
which typically accounts for a minimal total course of 5-7 
days [22]. After treatment for 14 days with doxycycline, 
our patient had no subjective complaints, while his physi-
cal and laboratory findings were normal.
The human ehrlichiosis is a newly identified disease 
that is still being rarely diagnosed. Ehrlichiosis should be 
considered in each case where there is a history of tick bite 
together with clinical picture (high fever, chills, muscle 
aches, headache, generalized weakness and malaise, and 
possible maculopapular rash). The diagnosis is made with 
high certainty using serological assays, and the disease is 
effectively treated with doxycycline.
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КРАТАК САДРЖАЈ
Увод Ер  ли  хи  о  за је бак  те  риј  ска зо  о  но  за ко  ја се пре  но  си хе-
ма  то  фаг  ним ар  тро  по  да  ма – кр  пе  љи  ма. Код љу  ди се ја  вља 
као мо  но  цит  на, гра  ну  ло  цит  на и ewin gii ер  ли  хи  о  за. Па  то  ло-
шки про  цес је по  сле  ди  ца уну  тар  ће  лиј  ског па  ра  зи  ти  ра  ња 
ер  ли  хи  је у мо  но  ци  ти  ма и гра  ну  ло  ци  ти  ма пе  ри  фер  не кр  ви.
При  каз бо  ле  сни  ка Бо  ле  сник стар 52 го  ди  не при  мљен је на 
оде  ље  ње због ви  со  ке дво  днев  не фе  брил  но  сти (пре  ко 40°C) 
ко  ја је пра  ће  на дрх  та  ви  цом, бо  ло  ви  ма у ми  ши  ћи  ма, ма  лак-
са  ло  шћу, гу  бит  ком апе  ти  та, гла  во  бо  љом, кон  фу  зно  шћу, оте-
жа  ним ди  са  њем и оскуд  ним су  вим ка  шљем. У анам  не  зи је 
до  би  јен по  да  так о ује  ду кр  пе  ља се  дам да  на пре при  је  ма. 
Ла  бо  ра  то  риј  ски на  ла  зи су ука  за  ли на тром  бо  ци  то  пе  ни  ју, 
ле  у  ко  пе  ни  ју, ане  ми  ју и по  ве  ћа  ње ак  тив  но  сти тран  са  ми-
на  за у се  ру  му. Бо  ле  сник је ле  чен док  си  ци  кли  ном 14 да  на, 
на  кон че  га су се те  го  бе по  ву  кле. Ме  то  дом ин  ди  рект  не иму-
но  флу  о  ре  сцен  ци  је ана  ли  зи  ра  на су три узор  ка се  ру  ма овог 
бо  ле  сни  ка на при  су  ство ан  ти  те  ла на бак  те  ри  ју Ehr lic hia chaf­
fe en sis и пре  гле  дан је узо  рак раз  ма  за пе  ри  фер  не кр  ви на 
при  су  ство ер  ли  хи  ја и кон  гло  ме  ра  та ер  ли  хи  је у мо  ру  ле, ко  је 
пред  ста  вља  ју ци  то  пла  змат  ске ва  ку  о  ле.
За  кљу  чак Код бо  ле  сни  ка с по  дат  ком о убо  ду кр  пе  ља, од-
го  ва  ра  ју  ћом кли  нич  ком сли  ком и се  ро  ло  шким те  стом ин-
ди  рект  не иму  но  флу  о  ре  сцен  ци  је до  ка  за  на су ан  ти  те  ла за 
бак  те  ри  ју Ehr lic hia chaf fe en sis, што ука  зу  је на ху  ману мо  но  ци-
то  троп  ну ер  ли  хи  о  зу, бо  лест ко  ја се код нас рет  ко до  ка  зу  је. 
На ер  ли  хи  о  зу тре  ба ми  сли  ти ка  да уз кли  нич  ку сли  ку (ви  со-
ка фе  брил  ност, гро  зни  ца, бо  ло  ви у ми  ши  ћи  ма, гла  во  бо  ља, 
оп  шта сла  бост и ма  лак  са  лост, евен  ту  ал  но ма  ку  ло  па  пу  ло  зна 
оспа) по  сто  ји по  да  так о убо  ду кр  пе  ља.
Кључ  не ре  чи: Ehr lic hia chaf fe en sis; ху  ма  на ер  ли  хи  о  за; ин  ди-
рект  на иму  но  флу  о  ре  сцен  ци  ја; док  си  ци  клин
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